Trinity Innovation Bioventure Singapore

We support the development of novel medicines that address significant unmet medical needs. As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making. Investment strategy and approach Our investment and portfolio construction strategy builds on lessons learned and approaches perfected during the 15 years the founding team worked together. We invest in companies that are about to enter the most value-generating phase of drug development i.e. clinical stage. Our capital helps answer the question “Is there a drug that works here?” We can lead, co-lead or follow. We (almost) always take Board seats in companies we invest in and lay particular emphasis on aligning our investment objectives to fellow investors’ investment interests. We always reserve capital for future capital raises and do not do investments in which we cannot. We invest in companies where it is possible for a private investor or venture syndicate to finance the R&D program all the way to regulatory approval. Therapeutic area focus All modalities and therapeutic areas are in scope as long as the biotech company is developing a novel medicine. Out of scope are investments that are, in our judgment, incremental innovation or a pureplay regulatory or pricing story. Medical devices, digital health and diagnostics companies are out of scope. Stage of company We invest in about-to-be clinical and clinical stage companies where the investment will result in a clinical readout for the lead asset. We can invest in any private financing round irrespective of whether its termed Series A, B, C or Cross-over Platform companies are also attractive, as long as the lead asset will get to a clinical readout with the financing. Geographic footprint We invest in companies in Europe and United States. We lay particular emphasis in investing in companies with Scandinavian roots, like our Firm has, and often start and build companies in Swedish and Danish ecosystem. Diseases afflicting people does not recognize geographic boundaries, science is global, financial capital is globally distributed and human capital is globally mobile. Therefore, we believe companies need to be built with that global perspective in mind. Our Core Values DECENT We show respect at all times We act with integrity and always aim to do the right thing Being reasonable builds long-term relationships DEDICATED We work hard to deliver results for patients, our companies and our LPs We are highly professional We love what we do CONFIDENT Our combined experience is extensive – we have been there before We trust our capabilities We are supported by a strong and extensive network HUMBLE We know our limitations We know when to listen and when to ask questions We are responsible stewards of our LP’s capital

Curie.Bio is a unique combination of two businesses: we act as both your drug discovery copilot & seed investor. We have some of the world’s best drug hunters, drug makers, experts, and vendors supporting our founders to increase their chances of developing successful medicines. By support, we don’t mean just a couple of hours a month. We are in the trenches with you on a day-to-day basis operating as fully integrated members of your team. We help you choose therapeutic targets, set milestones based on investor feedback, and design experimental plans. We interview and select drug discovery vendors to enable you to hit those milestones. We help identify what expertise needs to be brought in to support your key programs and then get you the right experts. We evaluate incremental data readouts with you to help determine which experiments need to be adjusted from the initial plan. We do real work. When you’re ready for your Series A, we work with you end-to-end on your data room, deck, and pitch. We make investor intros and coach you on how to run an excellent fundraising process to optimize the quality of your round. Curie.Bio’s model gives you a higher chance of success & reduces future dilution. How? By working with us, you make significant progress on your lead program(s) while being extremely capital efficient. We provide real help designing and executing your seed plan, including navigating the bumps, twists, and turns all along the way. This progress leads to better terms when raising a Series A & Series B. Investors now have a clear line of sight to getting your lead program(s) into the clinic. Post Curie.Bio’s seed, founders are positioned to raise significant capital to advance their programs without giving up as much future equity in their company. Simply put: better planning and more progress at the seed means a significantly higher chance of a future where you retain control, upside, and agency over your own company. Why us?Our team has brought over 60 drugs into the clinic with 12 approvals. Our team has founded biotech companies with more than $30 billion in enterprise value. We aim to bring our decades of experience to founders across the globe and have raised over $500m to make our vision a reality. We started with a problem statement: you can’t start a therapeutics company in your garage. Drug discovery is an incredibly complex process with multiple points of failure, particularly in the earliest stages of building a new company. We’re launching with a big idea: if we can help founders avoid mistakes, ensure they have the right data, plan & story, all while retaining the incentive to build their own company, we could in essence, free the founders. We believe the single greatest unlock of innovation in biotech over the next decade will come from creating more founders – more risk takers – more scientists with phenomenal ideas who have the support they need to start their own company.

K2HV’s investment professionals bring together substantial experience across multiple verticals in healthcare finance and operations, as well as considerable scientific knowledge. Our diverse backgrounds and experience give us a deep understanding of the needs of innovative healthcare companies throughout their lifecycles, and underpin our innovative and creative approach to investing. Our leadership team has committed more than $4 billion to over 100 private and public companies in the life sciences and healthcare industries. High Impact Investments, Long-Term ViewUniquely flexible, permanent capital structure enables us to provide long-term financing solutions and meet the evolving capital needs of growing companies Broad investment mandate allows us to be creative with financing structures Primary focus on customized debt financings, but able to invest in equity as well

Our portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. We take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Our global investment professionals bring deep scientific, medical and business knowledge to every investment we make. In an increasingly globalized economy, Vertex Ventures HC offers global expertise to companies around the world. With offices in Silicon Valley and Singapore, our investment team scouts and invests in promising companies in the U.S., Asia and beyond. Our team, along with our network of scientific advisors and venture partners, has deep local networks and capabilities in both emerging and established markets. Our agile structure means we can act quickly on investment opportunities.

Our expertise in biopharma and biotech investments. With decades of experience and a robust network within the biopharma and biotech industries, our team offers unparalleled insight into the scientific and financial landscapes. We are dedicated to identifying transformative therapies and supporting companies that are pioneering the future of healthcare. Empowering entrepeneurs to build leading companies Biovance Capital works closely with entrepreneurs to build leading companies with transformative treatments for patients in need. Stage: We invest in early-stage companies at seed and Series A rounds across Europe, with a focus in Southern countries. Technology: We invest in biotech companies developing therapeutics in any modality and therapeutic area. We require robust and appropriate preclinical models and patented or patentable assets before investing. Market: Large target market with a clear regulatory pathway for approval, with favorable reimbursement and pricing policies. Exit Potential: Sectors with VC/M&A or IPO activity, featuring profitable exits and multiple potential acquirers. Sustainability: During the due diligence process, sustainability risks are taken into account, and whenever identified, mitigation measures are proposed.

At Pappas Capital, we are dedicated to furthering life science discoveries and bringing groundbreaking solutions to market. Pappas Capital is laser focused on the life science sector. For more than 28 years we have been investing in and building innovative companies that are developing the next generation of life science products and technologies. We’ve invested in more than 85 companies across the United States and Canada – in fields that span the range of human disease. The products our companies have brought to market – for treating such conditions as melanoma, ovarian cancer, and hemophilia, to name a few – have been used throughout the world to treat tens of thousands of patients and account for billions of dollars of revenue. Whether you’re looking for capital or have capital to invest, contact us and learn how we can put our expertise to work for you.